348 related articles for article (PubMed ID: 12097601)
1. Pharmacological cyclin-dependent kinase inhibitors inhibit replication of wild-type and drug-resistant strains of herpes simplex virus and human immunodeficiency virus type 1 by targeting cellular, not viral, proteins.
Schang LM; Bantly A; Knockaert M; Shaheen F; Meijer L; Malim MH; Gray NS; Schaffer PA
J Virol; 2002 Aug; 76(15):7874-82. PubMed ID: 12097601
[TBL] [Abstract][Full Text] [Related]
2. Roscovitine, a specific inhibitor of cellular cyclin-dependent kinases, inhibits herpes simplex virus DNA synthesis in the presence of viral early proteins.
Schang LM; Rosenberg A; Schaffer PA
J Virol; 2000 Mar; 74(5):2107-20. PubMed ID: 10666240
[TBL] [Abstract][Full Text] [Related]
3. Requirement for cellular cyclin-dependent kinases in herpes simplex virus replication and transcription.
Schang LM; Phillips J; Schaffer PA
J Virol; 1998 Jul; 72(7):5626-37. PubMed ID: 9621021
[TBL] [Abstract][Full Text] [Related]
4. Effects of pharmacological cyclin-dependent kinase inhibitors on viral transcription and replication.
Schang LM
Biochim Biophys Acta; 2004 Mar; 1697(1-2):197-209. PubMed ID: 15023361
[TBL] [Abstract][Full Text] [Related]
5. Transcription of herpes simplex virus immediate-early and early genes is inhibited by roscovitine, an inhibitor specific for cellular cyclin-dependent kinases.
Schang LM; Rosenberg A; Schaffer PA
J Virol; 1999 Mar; 73(3):2161-72. PubMed ID: 9971799
[TBL] [Abstract][Full Text] [Related]
6. Roscovitine inhibits activation of promoters in herpes simplex virus type 1 genomes independently of promoter-specific factors.
Diwan P; Lacasse JJ; Schang LM
J Virol; 2004 Sep; 78(17):9352-65. PubMed ID: 15308730
[TBL] [Abstract][Full Text] [Related]
7. Cyclin-dependent kinases as cellular targets for antiviral drugs.
Schang LM
J Antimicrob Chemother; 2002 Dec; 50(6):779-92. PubMed ID: 12460995
[TBL] [Abstract][Full Text] [Related]
8. Five years of progress on cyclin-dependent kinases and other cellular proteins as potential targets for antiviral drugs.
Schang LM; St Vincent MR; Lacasse JJ
Antivir Chem Chemother; 2006; 17(6):293-320. PubMed ID: 17249245
[TBL] [Abstract][Full Text] [Related]
9. Cellular proteins (cyclin dependent kinases) as potential targets for antiviral drugs.
Schang LM
Antivir Chem Chemother; 2001; 12 Suppl 1():157-78. PubMed ID: 11594683
[TBL] [Abstract][Full Text] [Related]
10. Herpes simplex viruses in antiviral drug discovery.
Schang LM
Curr Pharm Des; 2006; 12(11):1357-70. PubMed ID: 16611120
[TBL] [Abstract][Full Text] [Related]
11. Cdk inhibitory nucleoside analogs prevent transcription from viral genomes.
Schang LM; Coccaro E; Lacasse JJ
Nucleosides Nucleotides Nucleic Acids; 2005; 24(5-7):829-37. PubMed ID: 16248044
[TBL] [Abstract][Full Text] [Related]
12. Advances on cyclin-dependent kinases (CDKs) as novel targets for antiviral drugs.
Schang LM
Curr Drug Targets Infect Disord; 2005 Mar; 5(1):29-37. PubMed ID: 15777196
[TBL] [Abstract][Full Text] [Related]
13. The differential requirement for cyclin-dependent kinase activities distinguishes two functions of herpes simplex virus type 1 ICP0.
Davido DJ; Von Zagorski WF; Maul GG; Schaffer PA
J Virol; 2003 Dec; 77(23):12603-16. PubMed ID: 14610183
[TBL] [Abstract][Full Text] [Related]
14. Potential use of pharmacological cyclin-dependent kinase inhibitors as anti-HIV therapeutics.
Pumfery A; de la Fuente C; Berro R; Nekhai S; Kashanchi F; Chao SH
Curr Pharm Des; 2006; 12(16):1949-61. PubMed ID: 16787240
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of human immunodeficiency virus type 1 transcription by chemical cyclin-dependent kinase inhibitors.
Wang D; de la Fuente C; Deng L; Wang L; Zilberman I; Eadie C; Healey M; Stein D; Denny T; Harrison LE; Meijer L; Kashanchi F
J Virol; 2001 Aug; 75(16):7266-79. PubMed ID: 11461999
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of cyclin-dependent kinase 1 by purines and pyrrolo[2,3-d]pyrimidines does not correlate with antiviral activity.
Evers DL; Breitenbach JM; Borysko KZ; Townsend LB; Drach JC
Antimicrob Agents Chemother; 2002 Aug; 46(8):2470-6. PubMed ID: 12121920
[TBL] [Abstract][Full Text] [Related]
17. Antiviral drugs that target cellular proteins may play major roles in combating HIV resistance.
Provencher VM; Coccaro E; Lacasse JJ; Schang LM
Curr Pharm Des; 2004; 10(32):4081-101. PubMed ID: 15579090
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological cyclin-dependent kinase inhibitors as HIV-1 antiviral therapeutics.
de la Fuente C; Maddukuri A; Kehn K; Baylor SY; Deng L; Pumfery A; Kashanchi F
Curr HIV Res; 2003 Apr; 1(2):131-52. PubMed ID: 15043199
[TBL] [Abstract][Full Text] [Related]
19. Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA.
Chen H; Teng L; Li JN; Park R; Mold DE; Gnabre J; Hwu JR; Tseng WN; Huang RC
J Med Chem; 1998 Jul; 41(16):3001-7. PubMed ID: 9685239
[TBL] [Abstract][Full Text] [Related]
20. The cyclin-dependent kinase inhibitor roscovitine inhibits the transactivating activity and alters the posttranslational modification of herpes simplex virus type 1 ICP0.
Davido DJ; Leib DA; Schaffer PA
J Virol; 2002 Feb; 76(3):1077-88. PubMed ID: 11773384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
